Heron Phamra News｜NMPA Approves First Tocalcitol Ointment Generic Drug- Hafuirun®
On Jan. 21st, 2021, National Medical Products Administration (NMPA) approved the commercialization of Heron Pharma’s Tacalcitol Ointment, with License number of "GYZX20213024". 24 years later, the First Generic Drug of Tacalcitol Ointment was born in China!
Tacalcitol ointment originally developed by Teijin Pharma Limited, it’s an active VD3 therapeutic agent for the treatment of hyperkeratotic diseases. Clinically, it is mainly used to treat patients with psoriasis vulgaris with less irritation and good tolerance, and can be used on the face or rubbing skin surface. It has been recommended as the first-line drug in the “Guideline for the Treatment of Diagnosis Psoriasis in China (Full Edition 2018)”. The originator was imported to China in 1997 and entered the national medical insurance category B directory through negotiation in 2019.
After 6 years of research and development, Haifurun® (Tacalcitol Ointment) is the first commercialized drug of Heron Pharma from Vitamin D derivatives. It fills the vacancy of Tacalcitol Ointment domestic supply in the past 24 years and provides more choices for clinical patients in psoriasis treatment.
Post time: Jan-21-2021